COVID-19 CLINICAL TRIAL RESEARCH STUDY

ENROLLING PATIENT VOLUNTEERS NOW!

Eligible Participants Who Complete the Study Receive $3400 in Compensation
NOLA Research Works is conducting clinical trial research for a promising antibody medication designed to treat COVID-19. Developed by pharmaceutical giant, Eli Lilly, the antibody medicine has shown a 72-percent risk reduction of hospitalization in patients with mild to moderate symptoms of the virus.

FREE COVID-19 RAPID TEST FOR PATIENTS WHO MEET OUR CRITERIA

Free testing is available to potential clinical trial patient volunteers who meet the following criteria:

  1. At Least 2 Symptoms of COVID-19
    Symptoms of COVID-19 include, but may not be limited to patients who are currently experiencing: Fever, cough, sore throat, achy/not feeling well, headache, muscle pain, digestive issues, and shortness of breath when active
  2. Underlying Medical Conditions
    Underlying medical conditions include, but may not be limited to: Obesity, kidney disease, diabetes, immunosuppression, cardiovascular disease, hypertension, and COPD
  3. Meaningful Interest in Participating in Our Study, If Test Results are Positive
    The Eli Lilly BLAZE-1 Study is designed to test how effective the antibody medicine LY-CoV555 is as a treatment for COVID-19. LY-CoV555 is an antibody from a blood sample taken from one of the first patients who recovered from COVID-19, and is specifically designed to neutralize the virus. The study will last approximately 12 weeks, including 1 required visit at the study site and the remainder in-home or by phone. Patient volunteers who complete the study will receive $3400 compensation.

Benefits to participation in our study include: 1. Antibody medicine proven to treat the COVID-19 virus, 2. Quality, comprehensive health care provided by a team of MD’s, RN’s, and research professionals, 3. Contribution to help find a cure, and 4. $3400 compensation to patient volunteers who complete the study.

Important Note: The correlation between testing eligibility and a patients’ health condition is fluid, and a direct reflection of the requirements of our Eli Lilly clinical trial research study at the time a patient may need to be tested for COVID-19. While an interested patient who has 2 or more symptoms and underlying medical conditions is a standard of our study, Eli Lilly often includes patients who don’t have underlying conditions. The best way to determine your eligibility for receiving a Free COVID-19 Rapid Test is to complete the Register Now form on this web page.

REGISTER TO DETERMINE YOUR ELIGIBILITY FOR OUR FREE RAPID TEST

Free COVID-19 Rapid Testing through NOLA Research Works is directly tied to our clinical trial research study and is only available to patients who meet Eli Lilly’s criteria. Patients who schedule a test are subject to evaluation by a healthcare provider to confirm symptoms, and if applicable, underlying conditions, prior to testing. If a patient does not meet the requirements, the patient may not be granted testing access.

For questions, please call 504-534-3111.

Your Path to Participacion

Complete the Registration form on this page. If you qualify through registration, you will be provided the opportunity to schedule an appointment within 48 hours.
If you pre-qualify through Registration, you can schedule an appointment at the research clinic on South White Street in Mid-City New Orleans.
During your appointment, you will be screened to confirm mild to moderate symptoms, complete informed consent agreement, and take a nasal swab test for COVID-19.

Helpful Documents About the Study

View and Download by Clicking on Documents

PRESS RELEASE 1
July 29, 2020

PRESS RELEASE 2
Sept, 18 2020

COVID-19 BLAZE Study

NEW ORLEANS

Kaye Doiron
CEO, NOLA Research Works

Corey Hebert, M.D.
Principal Investigator

An Opportunity for Our Entire Community
NOLA Research Works is the only clinical trials research site in the area invited
to participate in this exciting study by pharmaceutical giant, Eli Lilly and Company. With a quota of one hundred patient volunteers, we are actively recruiting participants into the study and urge the entire New Orleans community to embrace this opportunity.